Because of these properties, the iNOS/NO pathway represents a potential therapeutic target—research is underway on iNOS inhibitors and strategies to modulate NO production in the context of glioblastoma combination therapy [63,64,65]. This evidence concerns the gene NOS2 and glioblastoma.